Suppr超能文献

红参提取物及人参皂苷 Rc 与缬沙坦在大鼠体内的药物-药物相互作用。

Herb-Drug Interaction of Red Ginseng Extract and Ginsenoside Rc with Valsartan in Rats.

机构信息

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.

College of Pharmacy, Dankook University, Cheon-an 31116, Korea.

出版信息

Molecules. 2020 Jan 31;25(3):622. doi: 10.3390/molecules25030622.

Abstract

The purpose of this study was to investigate the herb-drug interactions involving red ginseng extract (RGE) or ginsenoside Rc with valsartan, a substrate for organic anion transporting polypeptide (OATP/Oatp) transporters. In HEK293 cells overexpressing drug transporters, the protopanaxadiol (PPD)-type ginsenosides- Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2-inhibited human OATP1B1 and OATP1B3 transporters (IC values of 7.99-68.2 µM for OATP1B1; 1.36-30.8 µM for OATP1B3), suggesting the herb-drug interaction of PPD-type ginsenosides involving OATPs. Protopanaxatriol (PPT)-type ginsenosides-Re, Rg1, and Rh1-did not inhibit OATP1B1 and OATP1B3 and all ginsenosides tested didn't inhibit OCT and OAT transporters. However, in rats, neither RGE nor Rc, a potent OATP inhibitor among PPD-type ginsenoside, changed in vivo pharmacokinetics of valsartan following repeated oral administration of RGE (1.5 g/kg/day for 7 days) or repeated intravenous injection of Rc (3 mg/kg for 5 days). The lack of in vivo herb-drug interaction between orally administered RGE and valsartan could be attributed to the low plasma concentration of PPD-type ginsenosides (5.3-48.4 nM). Even high plasma concentration of Rc did not effectively alter the pharmacokinetics of valsartan because of high protein binding and the limited liver distribution of Rc. The results, in conclusion, would provide useful information for herb-drug interaction between RGE or PPD-type ginsenosides and Oatp substrate drugs.

摘要

本研究旨在探讨红参提取物(RGE)或人参皂苷 Rc 与缬沙坦(有机阴离子转运多肽(OATP/Oatp)转运体的底物)之间的草药-药物相互作用。在过表达药物转运体的 HEK293 细胞中,原人参二醇(PPD)型人参皂苷-Rb1、Rb2、Rc、Rd、Rg3、化合物 K 和 Rh2 抑制人 OATP1B1 和 OATP1B3 转运体(IC50 值分别为 7.99-68.2 μM 用于 OATP1B1;1.36-30.8 μM 用于 OATP1B3),提示 PPD 型人参皂苷涉及 OATPs 的草药-药物相互作用。原人参三醇(PPT)型人参皂苷-Re、Rg1 和 Rh1 不抑制 OATP1B1 和 OATP1B3,且所有测试的人参皂苷均不抑制 OCT 和 OAT 转运体。然而,在大鼠中,无论是 PPD 型人参皂苷中强效 OATP 抑制剂的 RGE 还是 Rc,在重复口服给予 RGE(1.5 g/kg/天,连续 7 天)或重复静脉注射 Rc(3 mg/kg,连续 5 天)后,均不改变缬沙坦的体内药代动力学。口服给予的 RGE 和缬沙坦之间不存在体内草药-药物相互作用可能归因于 PPD 型人参皂苷的低血浆浓度(5.3-48.4 nM)。即使 Rc 的血浆浓度较高,由于其与蛋白的高结合率和有限的肝脏分布,也不能有效改变缬沙坦的药代动力学。综上所述,这些结果将为 RGE 或 PPD 型人参皂苷与 Oatp 底物药物之间的草药-药物相互作用提供有用的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd4b/7037682/2a0989337156/molecules-25-00622-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验